No Data
No Data
Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 1.03 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 12, $Regeneron Pharmaceuticals(REGN.US)$ Officer SCHLEIFER LEONARD S intends to sell 1,000 shares of its common stock on Jun 12, with a total market value of approximately
Pancreatic Cancer on the Rise: How Biotech Firms Are Developing Groundbreaking Treatments
After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may ...
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
CCORF analyst John Newman maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,152.According to TipRanks data, the analyst has a success rate of 39.0%
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Wells Fargo analyst Mohit Bansal maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,125.According to TipRanks data, the analyst has a success rate o
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $1,125 to $1,229
On Jun 12, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals(REGN.US)$, with price targets ranging from $1,125 to $1,229.Morgan Stanley analyst Terence Flynn maintains wit
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050
Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,229, according to analysts polled by Capital IQ.
No Data
RDK79 : I recognized one word in that lead sentence:)))
But it sounds like good news!!!